Enkephalin Therapy Improves Relapsing-Remitting Multiple Sclerosis
Multiple sclerosis (MS) is accompanied by decreases in serum endogenous enkephalin/endorphins and alterations in inflammatory cytokines. This retrospective analysis of serum levels was conducted in 53 patients with established relapsing-remitting MS treated with the disease-modifying therapies (DMT)...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2020
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/70924 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Enkephalin Therapy Improves Relapsing-Remitting Multiple Sclerosis
- Pharmacoeconomic evaluation of Ofatumumab in the management of relapsing-remitting multiple sclerosis patients: Narrative review
- Gene Therapy Approach: HSV-Enkephalin Reduces Fibrosis, Inflammation, and Pain
- Evolving Therapies in Relapsed and Refractory Hodgkin Lymphoma
- Therapy for Relapsed and Refractory Pediatric Hodgkin Lymphoma
- Cytoflavin in the Complex Therapy of Multiple Sclerosis
- Cellular Based Therapies for the Treatment of Multiple Sclerosis